Treatment with soybean-derived Bowman Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude mice
✍ Scribed by Wan, X. Steven; Ware, Jeffrey H.; Zhang, Lili; Newberne, Paul M.; Evans, Sydney M.; Clark, Larry C.; Kennedy, Ann R.
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 282 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
Bowman birk inhibitor (bbi) is an anticarcinogenic serine protease inhibitor that may inhibit the protease activity of prostate-specific antigen (psa) and the growth of human prostate cancer xenografts in nude mice.
Methods:
Human prostate cancer xenografts were established by implanting lncap cells into the prostate glands of ncrnu-m athymic nude mice. the animals with established tumors were maintained on a control diet or diets supplemented with 1% bbi or 1%, 2%, or 3% bbi concentrate (bbic) for 6 weeks. the serum psa concentrations were determined before and after the bbi or bbic treatment period. the final tumor loads were determined at autopsy.
Results:
Treatment with bbi or bbic decreased the final tumor load and increased the tumor doubling time and psa density in the nude mice bearing human prostate cancer xenografts.
Conclusions:
Bbi and/or bbic could be useful for prostate cancer treatment.